These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30640175)

  • 1. Cellular therapy against public neoantigens.
    Armistead PM
    J Clin Invest; 2019 Feb; 129(2):506-508. PubMed ID: 30640175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
    van der Lee DI; Reijmers RM; Honders MW; Hagedoorn RS; de Jong RC; Kester MG; van der Steen DM; de Ru AH; Kweekel C; Bijen HM; Jedema I; Veelken H; van Veelen PA; Heemskerk MH; Falkenburg JHF; Griffioen M
    J Clin Invest; 2019 Feb; 129(2):774-785. PubMed ID: 30640174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.
    Forghieri F; Riva G; Lagreca I; Barozzi P; Bettelli F; Paolini A; Nasillo V; Lusenti B; Pioli V; Giusti D; Gilioli A; Colasante C; Galassi L; Catellani H; Donatelli F; Talami A; Maffei R; Martinelli S; Potenza L; Marasca R; Tagliafico E; Manfredini R; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML.
    van der Lee DI; Koutsoumpli G; Reijmers RM; Honders MW; de Jong RCM; Remst DFG; Wachsmann TLA; Hagedoorn RS; Franken KLMC; Kester MGD; Harber KJ; Roelofsen LM; Schouten AM; Mulder A; Drijfhout JW; Veelken H; van Veelen PA; Heemskerk MHM; Falkenburg JHF; Griffioen M
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
    Wirth TC; Kühnel F
    Front Immunol; 2017; 8():1848. PubMed ID: 29312332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia.
    Zhou W; Yu J; Li Y; Wang K
    Exp Hematol Oncol; 2022 Nov; 11(1):100. PubMed ID: 36384590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy.
    Yonezawa Ogusuku IE; Herbel V; Lennartz S; Brandes C; Argiro E; Fabian C; Hauck C; Hoogstraten C; Veld S; Hageman L; Teppert K; Koutsoumpli G; Griffioen M; Mockel-Tenbrinck N; Schaser T; de Groot R; Johnston ICD; Lock D
    Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101224. PubMed ID: 38516690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
    Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
    Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
    Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
    Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.
    Du Pisani LA; Shires K
    Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):106-14. PubMed ID: 26183674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.
    Mullighan CG; Kennedy A; Zhou X; Radtke I; Phillips LA; Shurtleff SA; Downing JR
    Leukemia; 2007 Sep; 21(9):2000-9. PubMed ID: 17597811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia.
    Forghieri F; Riva G; Lagreca I; Barozzi P; Vallerini D; Morselli M; Paolini A; Bresciani P; Colaci E; Maccaferri M; Gilioli A; Nasillo V; Messerotti A; Pioli V; Arletti L; Giusti D; Bettelli F; Celli M; Donatelli F; Corradini G; Basso S; Gurrado A; Cellini M; Trenti T; Marasca R; Narni F; Martelli MP; Falini B; Potenza L; Luppi M; Comoli P
    Oncotarget; 2019 Jan; 10(8):869-882. PubMed ID: 30783516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.
    Falini B; Sportoletti P; Martelli MP
    Curr Opin Oncol; 2009 Nov; 21(6):573-81. PubMed ID: 19770764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The human nucleophosmin 1 mutation A inhibits myeloid differentiation of leukemia cells by modulating miR-10b.
    Zou Q; Tan S; Yang Z; Wang J; Xian J; Zhang S; Jin H; Yang L; Wang L; Zhang L
    Oncotarget; 2016 Nov; 7(44):71477-71490. PubMed ID: 27669739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the biology of acute myeloid leukemia with mutated NPM1.
    Brunetti L; Gundry MC; Goodell MA
    Int J Hematol; 2019 Aug; 110(2):150-160. PubMed ID: 30632059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
    Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
    Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neoantigens and Whole-Exome Sequencing].
    Karasaki T; Nakajima J; Kakimi K
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):791-7. PubMed ID: 27431622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycolytic Enzyme PKM2 Mediates Autophagic Activation to Promote Cell Survival in NPM1-Mutated Leukemia.
    Wang L; Yang L; Yang Z; Tang Y; Tao Y; Zhan Q; Lei L; Jing Y; Jiang X; Jin H; Zou Q; Xian J; Zhang L
    Int J Biol Sci; 2019; 15(4):882-894. PubMed ID: 30906218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.